title: Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: a retrospective population-based cohort study, 2000-2009.
abstract: BACKGROUND
  Prostate cancer is the fifth most common cancer affecting men of all ages in China, but robust surveillance data on its occurrence and outcome is lacking. The specific objective of this retrospective study was to analyze the longitudinal trends of prostate cancer incidence, mortality, and survival in Shanghai from 2000 to 2009.
  
  
  METHODS
  A retrospective population-based cohort study was performed using data from a central district (Putuo) and a suburban district (Jiading) of Shanghai. Records of all prostate cancer cases reported to the Shanghai Cancer Registry from 2000 to 2009 for the two districts were reviewed. Prostate cancer outcomes were ascertained by matching cases with individual mortality data (up to 2010) from the National Death Register. The Cox proportional hazards model was used to analyze factors associated with prostate cancer survival.
  
  
  RESULTS
  A total of 1022 prostate cancer cases were diagnosed from 2000 to 2009. The average age of patients was 75 years. A rapid increase in incidence occurred during the study period. Compared with the year 2000, 2009 incidence was 3.28 times higher in Putuo and 5.33 times higher in Jiading. Prostate cancer mortality declined from 4.45 per 105 individuals per year in 2000 to 1.94 per 105 in 2009 in Putuo and from 5.45 per 105 to 3.5 per 105 in Jiading during the same period. One-year and 5-year prostate cancer survival rates were 95% and 56% in Putuo, and 88% and 51% in Jiading, respectively. Staging of disease, Karnofsky Performance Scale Index, and selection of chemotherapy were three independent factors influencing the survival of prostate cancer patients.
  
  
  CONCLUSIONS
  The prostate cancer incidence increased rapidly from 2000 to 2009, and prostate cancer survival rates decreased in urban and suburban Chinese populations. Early detection and prompt prostate cancer treatment is important for improving health and for increasing survival rates of the Shanghai male population.
authors.forename: Yi
authors.initials: Y
authors.lastname: Hu
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhao
authors.forename: Jianyu
authors.initials: J
authors.lastname: Rao
authors.forename: Haiju
authors.initials: H
authors.lastname: Deng
authors.forename: Hong
authors.initials: H
authors.lastname: Yuan
authors.affiliation: Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai 200032, China. bxu@shmu.edu.cn.
authors.forename: Biao
authors.initials: B
authors.lastname: Xu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002681:China / Q000453:epidemiology; D002947:Cities; D006801:Humans; D015994:Incidence; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000401:mortality*; D012107:Research Design; D012189:Retrospective Studies; D015996:Survival Rate; D014505:Urban Population
references.citation: Am Fam Physician. 1996 Jun;53(8):2751-2
references.pmid: 8644580
references.citation: Br J Urol. 1998 Jul;82(1):166
references.pmid: 9698691
references.citation: Eur Urol. 2012 Aug;62(2):204-9
references.pmid: 22541389
references.citation: Cancer Epidemiol. 2013 Jun;37(3):219-25
references.pmid: 23485480
references.citation: Nutr Cancer. 2012;64(1):48-56
references.pmid: 22136606
references.citation: Ann Oncol. 2012 Jan;23(1):251-256
references.pmid: 21467126
references.citation: Prostate. 2012 Dec 1;72(16):1779-88
references.pmid: 22514016
references.citation: N Engl J Med. 2012 Mar 15;366(11):981-90
references.pmid: 22417251
references.citation: Front Med. 2012 Sep;6(3):322-8
references.pmid: 22843305
references.citation: Semin Urol Oncol. 2002 Feb;20(1):3-9
references.pmid: 11828352
references.citation: Can J Urol. 2008 Jun;15(3):4056-64
references.pmid: 18570709
references.citation: J Public Health (Oxf). 2012 Mar;34(1):131-7
references.pmid: 21742740
references.citation: BMC Med. 2012 Sep 25;10:109
references.pmid: 23009325
references.citation: World J Urol. 2012 Apr;30(2):157-65
references.pmid: 22249340
references.citation: J Urol. 2012 Jul;188(1):73-83
references.pmid: 22578732
references.citation: World J Urol. 2012 Apr;30(2):143-8
references.pmid: 22116601
references.citation: Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):83-4
references.pmid: 9456247
references.citation: BMC Public Health. 2012 Nov 12;12:967
references.pmid: 23146089
references.citation: Eur Urol. 2010 Apr;57(4):631-8
references.pmid: 19299069
references.citation: Eur J Cancer. 2012 Jun;48(9):1341-6
references.pmid: 22516210
references.citation: BMC Cancer. 2012 Jan 18;12:23
references.pmid: 22257467
references.citation: Cardiol Res Pract. 2012;2012:178675
references.pmid: 21961074